Higgsfield initially saw high adoption for viral, consumer-facing AI features but pivoted. They realized foundation model players like OpenAI will dominate and subsidize these markets. The defensible startup strategy is to ignore consumer virality and solve specific, monetizable B2B workflow problems instead.

Faced with an "AI mandate," many companies try to force-fit AI onto their current offerings, leading to failure. The correct first step is a fundamental assessment: is this problem even a good candidate for AI, or does the entire product need to be reimagined from the ground up?

The true test for an AI tool isn't its initial, tailored function. The problem arises when a neighboring department tries to adapt it for their slightly different tech stack. The tool, excellent at one thing, gets "promoted into incompetency" when asked to handle broader, varied use cases across the enterprise.

The successful early adoption of AI in healthcare was brilliant because it first targeted the administrative burdens that clinicians hate, such as documentation (scribes) and billing. By winning the hearts and minds of powerful incumbents with immediate quality-of-life improvements, the industry built momentum for more complex clinical applications.

IBM CEO Arvind Krishna argues Watson's core AI tech was sound, but its failure stemmed from a closed, all-in-one product approach. The market, especially developers, preferred modular building blocks to create their own applications, a lesson that informed the WatsonX rebranding with LLMs.

Many AI projects become expensive experiments because companies treat AI as a trendy add-on to existing systems rather than fundamentally re-evaluating the underlying business processes and organizational readiness. This leads to issues like hallucinations and incomplete tasks, turning potential assets into costly failures.

Much like the big data and cloud eras, a high percentage of enterprise AI projects are failing to move beyond the MVP stage. Companies are investing heavily without a clear strategy for implementation and ROI, leading to a "rush off a cliff" mentality and repeated historical mistakes.

The primary reason most pharmaceutical AI projects fail to deliver value is not technical limitation but strategic failure. Organizations become obsessed with optimizing algorithms while neglecting the foundational blueprint that connects AI investment to measurable business outcomes and operational readiness.

The famous Watson AI failed not because of its technology, but its go-to-market strategy. IBM tried building a single, monolithic application in healthcare, the hardest vertical. Had it focused on a platform for broad enterprise use cases, it might have been five years ahead of the current AI boom.